Literature DB >> 31686877

Association between serum TSH levels and metabolic components in euthyroid subjects: a nationwide population-based study.

Rui Ren1,2, Yu Ma2, Fang Deng1, Tao Li1, Hongyan Wang2, Jing Wei3, Xiaoyan Jiang2, Min He1, Mingyuan Tian4, Dongfang Liu4, Bing Chen1, Wuquan Deng1,2.   

Abstract

BACKGROUND: Whether a relationship exists between various metabolic factors and thyroid-stimulating hormone (TSH) levels in euthyroid persons remains unknown. This study aims to explore the relationship between TSH levels and metabolic factors in euthyroid individuals.
METHODS: A total of 2,663 subjects were enrolled from a nationwide population-based cross-sectional survey of iodine nutrition, thyroid disease and diabetes in China (2014-2017). Euthyroid individuals were divided into four groups according to quartiles of TSH levels: group A (n=305, 0.3-1.3 mIU/L), group B (n=829, 1.3-2.2 mIU/L), group C (n=673, 2.2-3.2 mIU/L) and group D (n=349, 3.2-4.2 mIU/L). Anthropometric parameters, biochemical indicators and TSH levels were determined.
RESULTS: A total of 2,156 euthyroid subjects with serum TSH levels within the normal range accounted for 86.8% of the sample. The systolic blood pressure (SBP) in group D was significantly higher than that in the other three groups. Group C displayed significantly lower thyroid peroxidase antibody (TPOAb) levels than the other three groups. Group C also had lower anti-thyroglobulin antibody (TgAb) levels than groups A and D, whereas the TgAb levels in group B were only lower than those in group A. Spearman's or Pearson's linear regression analysis showed that SBP (r=0.054; P=0.013) was positively correlated with TSH, but cholesterol (TC) (r=-0.043, P=0.047) was negatively correlated with TSH. Multiple stepwise regression analysis revealed that SBP, the urinary iodine concentration (UIC), waist circumference (WC), body mass index (BMI), TC, triglycerides (TGs) and low-density lipoprotein cholesterol (LDL-C) were independent predictors of serum TSH levels.
CONCLUSION: This large population-based study demonstrates a significant interaction between metabolic factors and TSH levels. An adverse weight status, high blood pressure levels, blood lipid metabolism disorder and excessive iodine intake may be early manifestations of thyroid disease in euthyroid subjects.
© 2019 Ren et al.

Entities:  

Keywords:  euthyroid state; iodine nutrition; metabolic syndrome; thyroid-stimulating hormone

Year:  2019        PMID: 31686877      PMCID: PMC6709806          DOI: 10.2147/DMSO.S202769

Source DB:  PubMed          Journal:  Diabetes Metab Syndr Obes        ISSN: 1178-7007            Impact factor:   3.168


Introduction

Recently, the incidence of thyroid disease has sharply increased year by year.1 The proportion of individuals with elevated TSH levels in the general population is also increasing. Hypothyroidism and subclinical hypothyroidism (SCH) are very common diseases in the general population. The reported incidence of SCH ranges between 5% and 10% and is higher in older people and women.2 Based on a survey of the prevalence of thyroid diseases in 2010, the prevalence of SCH in China was 16.7% based on a diagnostic cut-off level of thyroid-stimulating hormone (TSH) >4.2 mIU/L. High TSH levels within the normal range may be a sign of early hypothyroidism and are associated with an increased prevalence of autoimmune thyroid disease and a risk of hypothyroidism in the near future.3 An increased serum TSH level may cause multiple organ damage and metabolism disorder.4–8 Inoue et al reported that a high-normal TSH level can increase the risk of all-cause, cardiovascular and cancer-related mortality compared with medium-normal TSH levels.4 Coronary heart disease has been reported to be associated with the lowest tertile of TSH levels in men.5 Fernándezreal-Real et al found a positive correlation between TSH and postprandial fasting insulin levels in healthy euthyroid subjects.6 Although the baseline TSH level was not associated with the risk of diabetes, after 84,595 person-years of follow-up, the TSH level was demonstrated to be an additional risk factor for the development of type 2 diabetes in euthyroid subjects.7 In early pregnancy, SCH and thyroperoxidase antibody-positive euthyroidism are associated with an increased risk of gestational diabetes mellitus.8 Additionally, glycemic aberrations are closely associated with TSH secretion in type 1 diabetes regardless of variations in thyroid hormone concentrations.9 However, in a previous meta-analysis, plasma TSH levels within the normal range had no significant relationship with the incidence of type 2 diabetes, even in patients with a high cardiovascular risk.10 In addition to the results of the above studies, the prevalence of metabolic syndrome in China has recently been reported to be as high as 33.9%;11 thus, disorder of the TSH level may be influenced by metabolic regulation factors. However, the results are not completely consistent in previous studies,4,5,7,10 and the underlying cause is not fully known. The possible reasons include small sample sizes, racial differences and participant selection from special populations. In addition, reports including the urinary iodine concentrations (UIC) are rare or conflicting. The relationship between iodine intake and TSH is unclear. Therefore, we performed a cross-sectional investigation based on a nationwide iodine nutrition and thyroid disease epidemiological survey to explore the relationship between TSH and thyroid antibody, the UIC, blood glucose, blood lipids, blood pressure, and other metabolic parameters in euthyroid subjects.

Subjects and methods

Study population

The National Survey of Iodine Nutrition, Thyroid Diseases and Diabetes (2014–2017) is a nationwide, cross-sectional survey of the Chinese general population. Participants were randomly selected from two urban and two rural communities in a southwest city with a population of thirty million inhabitants. A total of 2,663 participants aged 18 years or older (18–96 years old) were included in this study. Among these individuals, 180 subjects were excluded due to incomplete data. Thus, 2,483 subjects remained for the study analysis. The study subjects met the following inclusion criteria: (1) 18 years of age or older; (2) Han race; (3) residence in a community (village) for more than 5 years; (4) no iodine contrast agent examination or amiodarone intake in the past three months; and (5) nonpregnant women. The study was approved on April 25, 2013, by the ethics committee of the First Hospital of China Medical University (No. 2013-115), and written informed consent was obtained from all participants.

Anthropometric and biochemical measurements

Anthropometric parameters

All of the participants were required to fast overnight before the physical examination. The anthropometric parameters included height, weight, waist circumference (WC) and blood pressure. Height, weight, waist circumference and blood pressure were measured according to standard procedures reported in a previous study.12 The participants should rest for 10 mins before blood pressure measurement, relax their minds, avoid exertion, empty the bladder, stop smoking 15 mins before the test, avoid drinking tea and coffee, and be seated. The right upper limb blood pressure was measured twice per person for 3–5 mins each time.

Experimental procedures and determination methods

Overnight fasting blood samples were collected. All subjects were assayed for TSH, thyroid peroxidase antibody (TPOAb), anti-thyroglobulin antibody (TgAb), total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), blood uric acid (UA), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), and the UIC.12,13 The TSH, TPOAb and TgAb levels in the specimens were determined by immunochemiluminescence. The FBG level was assayed using the glucose oxidase method. The TC, TG, LDL-C, HDL-C and UA concentrations were determined enzymatically. The HbA1c level was determined using high-performance liquid chromatography. The UIC was uniformly determined with inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 7700×, Agilent Technologies, USA) in the central laboratory.

Definitions of thyroid function and the normal reference ranges

The subjects with normal thyroid function were divided into four groups according to quartiles of TSH levels: group A (n=305, 0.3–1.3 mIU/L), group B (n=829, 1.3–2.2 mIU/L), group C (n=673, 2.2–3.2 mIU/L), and group D (n=349, 3.2–4.2 mIU/L). The reference ranges were 0.3–4.2 mIU/L for TSH, 0–34 IU/mL for TPoAb, and 0–115 IU/mL for TgAb as provided by the central laboratory. When the serum TSH and FT4 levels were within the normal ranges, the subject was considered to have normal thyroid function.

Statistical analysis

The experimental data were processed with SPSS statistical software, version 22.0. Continuous variables are described as the means ± standard deviation, comparisons between multiple groups were performed with analysis of variance (ANOVA), and pairwise comparisons were performed with the least-significant difference (LSD) test. Correlations between variables were determined using Pearson’s or Spearman’s correlation analysis, and the independent influencing factors of TSH were explored through multiple stepwise regression analysis. A test level of P<0.05 was considered statistically significant.

Results

According to the analysis results of the samples, 2,156 euthyroid subjects with normal serum TSH levels remained after 327 individuals were excluded because of thyroid diseases. As presented in Table 1 and Figure 1, body mass index (BMI), WC, FBG, HbA1c, UA, TGs, TC, LDL-C and HDL-C did not differ among the groups. Comparisons of the groups showed that the systolic blood pressure (SBP) in group D was significantly higher than that in the other three groups. Group C displayed significantly lower TPoAb levels (Figure 1A) than those in the other three groups. Group C also had lower TgAb levels (Figure 1B) than those in group A and group D, whereas the TgAb levels in group B were only lower than those in group A. The difference of UIC levels between all groups were showed in Figure 1C.
Table 1

Comparison of the clinical characteristics of all groups

A (n=305)B (n=829)C (n=673)D (n=349)FP-value
Age43.81±15.6242.13±16.8941.92±17.5743.54±19.011.3820.247
BMI23.26±3.5023.28±3.5423.44±3.6323.47±3.750.4380.726
SBP118(110,131)120(111,130)119(109,132)123(111,136)a,b,c11.3230.010*
DBP78.19±11.8378.02±11.1978.15±11.3779.41±11.001.3360.261
WC80.64±9.9180.56±9.7080.38±10.0779.88±9.720.4570.713
HR77.34±12.0176.59±10.8876.78±10.6677.14±10.150.4500.717
FBG5.51±1.585.47±1.585.52±1.475.43±1.430.3260.806
TG1.54±1.331.52±1.411.60±1.521.59±1.310.5330.659
TC4.60±1.024.56±0.964.52±0.934.49±0.910.8970.442
LDL-C2.56±0.732.61±0.732.56±0.702.55±0.690.8180.484
HDL-C1.33±0.391.31±0.561.29±0.391.29±0.350.8380.473
UA345.72±98.11353.46±103.39356.57±110.39345.88±110.361.2120.304
HbA1c5.39±1.045.38±1.015.41±0.995.34±0.820.4240.736

Notes: aP<0.05 compared with group A. bP<0.05 compared with group B. cP<0.05 compared with group C.

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference; HR, heart rate; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; UA, uric acid; HbA1c, glycated hemoglobin.

Figure 1

Comparison of TPOAb (A), TgAb (B), and UIC (C) levels in all groups.

Notes: aP<0.05 compared with group A. bP<0.05 compared with group B. cP<0.05 compared with group C.

Abbreviations: TPOAb, thyroid peroxidase antibody; TgAb, anti-thyroglobulin antibodies; UIC, urinary iodine.

Comparison of the clinical characteristics of all groups Notes: aP<0.05 compared with group A. bP<0.05 compared with group B. cP<0.05 compared with group C. Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference; HR, heart rate; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; UA, uric acid; HbA1c, glycated hemoglobin. Comparison of TPOAb (A), TgAb (B), and UIC (C) levels in all groups. Notes: aP<0.05 compared with group A. bP<0.05 compared with group B. cP<0.05 compared with group C. Abbreviations: TPOAb, thyroid peroxidase antibody; TgAb, anti-thyroglobulin antibodies; UIC, urinary iodine. As presented in Figure 2, correlations were observed between TSH levels and SBP (r=0.054; P=0.013) (Figure 2A) and TC (r=−0.043, P=0.047) (Figure 2B). No correlations were found between the remaining metabolic indicators and TSH. Multiple stepwise regression analysis revealed that WC, BMI, SBP, TC, TGs, LDL-C and the UIC were independently related to TSH levels (Table 2).
Figure 2

The correlations between TSH and SBP (A) and TC (B).

Abbreviations: TSH, thyroid-stimulating hormone; SBP, systolic blood pressure; TC, total cholesterol.

Table 2

Multiple stepwise regression analysis of metabolic parameters and TSH levels

Nonstandardized coefficientStandardized coefficienttP-value
BStandard error
SBP0.0040.0010.0933.956<0.001
TC−0.1190.035−0.132−3.3740.001
UIC0.0000.000−0.045−2.0960.036
WC−0.0110.003−0.132−3.887<0.001
BMI0.020.0080.0842.580.01
TG0.0370.0150.0612.5270.012
LDL-C0.0920.0460.0772.0280.043
2.4320.18613.111<0.001

Abbreviations: TSH, thyroid-stimulating hormone; SBP, systolic blood pressure; TC, total cholesterol; UIC, urinary iodine concentration; WC, waist circumference; BMI, body mass index; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol.

Multiple stepwise regression analysis of metabolic parameters and TSH levels Abbreviations: TSH, thyroid-stimulating hormone; SBP, systolic blood pressure; TC, total cholesterol; UIC, urinary iodine concentration; WC, waist circumference; BMI, body mass index; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol. The correlations between TSH and SBP (A) and TC (B). Abbreviations: TSH, thyroid-stimulating hormone; SBP, systolic blood pressure; TC, total cholesterol.

Discussion

Thyroid disease is one of the most common endocrine system diseases. Hypothalamic-pituitary-thyroid axis-related hormone levels are slightly altered and may affect the body overall.14,15 Increased risks of thyroid disease and type 1 diabetes have been found in children born to women with Graves’ disease.16 TSH within the reference range has been reported to be positively associated with the risk of future hypothyroidism.3 The prevalence of metabolic syndrome in China is markedly high.11 Another study revealed that patients with metabolic syndrome had a 21% excess risk of developing SCH, even after controlling for risk factors during an average follow-up of 4.2 years.17 Whether early changes in serum TSH levels are related to metabolic indicators in euthyroid subjects is unclear. In the present study, SBP, as one of the metabolic syndrome components, was higher in the highest quartiles of TSH levels. The TSH level was also positively correlated with SBP. The results are consistent with those of a previous cross-sectional meta-analysis.18 The study enrolled 2,289 euthyroid individuals and identified strong evidence for a dose-response relationship between TSH levels and the hypertension risk. Individuals with higher normal TSH levels are at a higher risk of developing hypertension than those with lower normal TSH levels. This result was further supported by a meta-analysis suggesting a significant dose-response relationship between TSH levels and the hypertension risk in euthyroid subjects.19 In addition to influencing blood pressure, the effect of thyroid dysfunction on lipid metabolism is not fully clear.20 The thyroid is widely believed to be the target organ of lipotoxicity.21 TC and TG levels were positively correlated with TSH levels in euthyroid subjects in a previous study.22 However, the TC level was slightly negatively correlated with TSH levels in our study. Furthermore, the study found that lipid levels (TC and TG) were more likely to be abnormal in subjects with the lowest or highest quartiles of TSH levels. We speculated that a trend toward an abnormal TSH level substantially more adversely influenced blood lipid metabolism and related clinical outcomes than medium-normal TSH levels. These findings may explain why the highest or lowest normal TSH level can increase the risk of cardiovascular disease.4,5 Our hypothesis is further supported by a recent study reported by Ahi et al.23 Significantly elevated TPOAb and TgAb levels were observed in participants with the lowest and highest limits of TSH within the reference range. Thyroid-related antibody levels may be an early manifestation of thyroid diseases, especially autoimmune thyroid disease. A previous study also suggested that TPOAb and/or TgAb increased significantly with increasing levels of TSH and was associated with the prevalence of hypothyroidism.24,25 The UIC was highest in subjects with a TSH level of 1.3–2.2 mIU/L, which is also consistent with the findings of a previous study.26 Additionally, the UIC was negatively correlated with TSH levels in euthyroid subjects. More than adequate iodine intake may be an important inducing factor of thyroid disease. The prevalence of clinical hyperthyroidism and Graves’ disease has been reported to be significantly increased among Chinese populations in areas with adequate iodine intake.27 Metabolic syndrome components, weight status (BMI and WC), blood pressure, blood lipids and iodine status are all influenced by TSH levels. Adipocyte- and hepatocyte-derived metabolic regulators may be critical links between metabolic syndrome and thyroid function.28 The study results showing that WC and BMI were independently related to TSH levels are partly consistent with those of a previous Asian study revealing that men with a higher TSH concentration had higher body weights and BMI values, even after adjusting for related confounders. However, the TSH level was not associated with WC.29 A 1-mIU/L higher TSH level within the euthyroid or subclinical hypothyroid range was associated with a 0.51-kg higher baseline weight in women.30 In patients with SCH, high blood pressure and high serum TGs were associated with an increased risk of thyroid disease. Subjects with metabolic syndrome were reported to be at a greater risk of developing SCH.17 Thyroid hormone supplementation increased TSH levels, which reached a steady state at an incidence risk ratio of 1.75 after ten years of iodine fortification.31 Some inevitable limitations exist in our study. First, this study was cross-sectional, and the results should be verified by a longitudinal clinical study in the future. Second, comorbidities and concomitant drug use are common among elderly individuals. According to the literature, some drugs, such as estrogen, aspirin, nonsteroidal anti-inflammatory drugs, and glucocorticoids, can affect thyroid hormones.32 We hope to provide supporting data and references for future studies, and more studies are needed to clarify the relationship between metabolic indicators and thyroid disease.

Conclusion

In conclusion, metabolic parameters showed significant changes at different levels of TSH. Weight status, blood pressure, blood lipids and iodine intake were independent predictors of serum TSH levels. Disorder of various metabolic parameters is an important factor that cannot be ignored as an influencing factor of thyroid disease. Further studies are needed to explore the possible mechanism of metabolic syndrome and its influence on thyroid function.
  32 in total

1.  Hypothyroidism and intermediate metabolism: a complex relationship.

Authors:  Anna Solini; Fabio Monzani
Journal:  Thyroid       Date:  2010-08       Impact factor: 6.568

2.  TSH increment and the risk of incident type 2 diabetes mellitus in euthyroid subjects.

Authors:  Ji Eun Jun; Sang-Man Jin; Jae Hwan Jee; Ji Cheol Bae; Kyu Yeon Hur; Moon-Kyu Lee; Sun Wook Kim; Jae Hyeon Kim
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

3.  Association Between Serum Thyrotropin Levels and Mortality Among Euthyroid Adults in the United States.

Authors:  Kosuke Inoue; Tetsuro Tsujimoto; Jun Saito; Takehiro Sugiyama
Journal:  Thyroid       Date:  2016-09-13       Impact factor: 6.568

4.  Metabolic Syndrome Among Adults in China: The 2010 China Noncommunicable Disease Surveillance.

Authors:  Jieli Lu; Limin Wang; Mian Li; Yu Xu; Yong Jiang; Weiqing Wang; Jianhong Li; Shengquan Mi; Mei Zhang; Yichong Li; Tiange Wang; Min Xu; Zhiyun Zhao; Meng Dai; Shenghan Lai; Wenhua Zhao; Linhong Wang; Yufang Bi; Guang Ning
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

5.  Influence of thyroid dysfunction on serum levels of angiopoietin-like protein 6.

Authors:  Jung Ah Lim; Hyo Jeong Kim; Hwa Young Ahn; Kyoung Un Park; Ka Hee Yi; Do Joon Park; Hak Chul Jang; Young Joo Park
Journal:  Metabolism       Date:  2015-06-24       Impact factor: 8.694

6.  Maternal TSH level and TPOAb status in early pregnancy and their relationship to the risk of gestational diabetes mellitus.

Authors:  Hao Ying; Yu-Ping Tang; Yi-Rong Bao; Xiu-Juan Su; XueYa Cai; Yu-Hong Li; De-Fen Wang
Journal:  Endocrine       Date:  2016-07-16       Impact factor: 3.633

Review 7.  Clinical aspects of thyroid function during ageing.

Authors:  Layal Chaker; Anne R Cappola; Simon P Mooijaart; Robin P Peeters
Journal:  Lancet Diabetes Endocrinol       Date:  2018-07-17       Impact factor: 32.069

8.  Association between a serum thyroid-stimulating hormone concentration within the normal range and indices of obesity in Japanese men and women.

Authors:  Masaru Sakurai; Koshi Nakamura; Katsuyuki Miura; Katsushi Yoshita; Toshinari Takamura; Shin-ya Nagasawa; Yuko Morikawa; Masao Ishizaki; Teruhiko Kido; Yuchi Naruse; Motoko Nakashima; Kazuhiro Nogawa; Yasushi Suwazono; Hideaki Nakagawa
Journal:  Intern Med       Date:  2012-03-01       Impact factor: 1.271

9.  Treatment of pretibial myxedema with intralesional immunomodulating therapy.

Authors:  Ziwei Ren; Min He; Fang Deng; Yan Chen; Liyin Chai; Bing Chen; Wuquan Deng
Journal:  Ther Clin Risk Manag       Date:  2017-09-08       Impact factor: 2.423

10.  Chronic diseases in the children of women with maternal thyroid dysfunction: a nationwide cohort study.

Authors:  Line Riis Jølving; Jan Nielsen; Ulrik Schiøler Kesmodel; Rasmus Gaardskær Nielsen; Bente Mertz Nørgård; Signe Sparre Beck-Nielsen
Journal:  Clin Epidemiol       Date:  2018-09-28       Impact factor: 4.790

View more
  6 in total

1.  The Association Between Serum Palmitic Acid and Thyroid Function.

Authors:  Guowei Zhou; Yumeng Xu; Yuqing Zhai; Zhen Gong; Kun Xu; Gaoyuan Wang; Chenhua Sun; Chaoqun Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-03       Impact factor: 6.055

2.  Prevalence of Components of Metabolic Syndrome Among Adults with the Presence of Autoimmune Thyroid Condition in an Iodine-Sufficient Region.

Authors:  Binyu Pan; Qin Zhang; Hang Zhou; Zheng Feei Ma
Journal:  Biol Trace Elem Res       Date:  2020-10-02       Impact factor: 3.738

3.  The Association Between Serum Thyrotropin Within the Reference Range and Metabolic Syndrome in a Community-Based Chinese Population.

Authors:  Meng Li; Xiuying Zhang; Xianghai Zhou; Xueyao Han; Rui Zhang; Zuodi Fu; Lianying Wang; Ying Gao; Yufeng Li; Linong Ji
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-16       Impact factor: 3.168

4.  Association Between Serum Thyroid-Stimulating Hormone Levels and Salivary Microbiome Shifts.

Authors:  Ting Dong; Fen Zhao; Keyong Yuan; Xiaohan Zhu; Ningjian Wang; Fangzhen Xia; Yingli Lu; Zhengwei Huang
Journal:  Front Cell Infect Microbiol       Date:  2021-02-26       Impact factor: 5.293

5.  Gender-Specific Impact of Metabolic Obesity Phenotypes on the Risk of Hashimoto's Thyroiditis: A Retrospective Data Analysis Using a Health Check-Up Database.

Authors:  Hao Yang; Qing Xia; Yan Shen; Ting-Li Chen; Jing Wang; Ya-Yun Lu
Journal:  J Inflamm Res       Date:  2022-02-07

6.  The Relationship Between Metabolic Parameters, Age, and Thyroid Status: A Cross-Sectional Study-Based National Survey of Iodine Nutrition, Thyroid Disease.

Authors:  Bo Deng; Yi Yuan; Miao Zhong; Rui Ren; Wuquan Deng; Xiaodong Duan
Journal:  Risk Manag Healthc Policy       Date:  2021-04-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.